Phio Pharmaceuticals Corp, a United States-based biotechnology company, has signed a clinical development collaboration with United States-based AgonOx Inc.

It was reported on Monday that the contract has been signed to develop novel T cell-based cancer immunotherapies using Phio Pharmaceuticals Corporation's lead INTASYL based product candidate PH-762 and AgonOx's 'double positive' (DP) tumour-infiltrating lymphocyte (TIL) technology. Both firms have indicated that the combination of their respective technologies can result in improved TIL therapeutics, and based on these data, the partnership is to concentrate on conducting a clinical study for PH-762 treated double positive tumour-infiltrating lymphocyte. The study is likely to commence enrolling patients later this year.

According to the terms of the collaboration agreement, AgonOx is to receive financial support for the clinical trial from Phio and Phio is entitled to certain future development milestones and sales related royalty payments from AgonOx's DP TIL technology.